- Home
- SSSS vs ELUT Comparison
SSSS vs ELUT Comparison
Compare SSSS & ELUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSSS
- ELUT
- Stock Information
- Founded
- SSSS 2010
- ELUT 2015
- Country
- SSSS United States
- ELUT United States
- Employees
- SSSS N/A
- ELUT N/A
- Industry
- SSSS Finance: Consumer Services
- ELUT Medical Specialities
- Sector
- SSSS Finance
- ELUT Health Care
- Exchange
- SSSS Nasdaq
- ELUT Nasdaq
- Market Cap
- SSSS 118.1M
- ELUT 111.2M
- IPO Year
- SSSS N/A
- ELUT 2020
- Fundamental
- Price
- SSSS $4.91
- ELUT $4.40
- Analyst Decision
- SSSS Buy
- ELUT Strong Buy
- Analyst Count
- SSSS 2
- ELUT 2
- Target Price
- SSSS $6.00
- ELUT $10.00
- AVG Volume (30 Days)
- SSSS 177.4K
- ELUT 23.7K
- Earning Date
- SSSS 11-07-2024
- ELUT 11-14-2024
- Dividend Yield
- SSSS N/A
- ELUT N/A
- EPS Growth
- SSSS N/A
- ELUT N/A
- EPS
- SSSS N/A
- ELUT N/A
- Revenue
- SSSS $5,903,895.00
- ELUT $24,782,000.00
- Revenue This Year
- SSSS N/A
- ELUT $9.65
- Revenue Next Year
- SSSS $6.05
- ELUT $39.29
- P/E Ratio
- SSSS N/A
- ELUT N/A
- Revenue Growth
- SSSS 5.43
- ELUT N/A
- 52 Week Low
- SSSS $3.32
- ELUT $1.64
- 52 Week High
- SSSS $5.44
- ELUT $5.24
- Technical
- Relative Strength Index (RSI)
- SSSS 53.68
- ELUT 69.22
- Support Level
- SSSS $4.81
- ELUT $3.57
- Resistance Level
- SSSS $5.44
- ELUT $4.42
- Average True Range (ATR)
- SSSS 0.27
- ELUT 0.33
- MACD
- SSSS -0.03
- ELUT 0.09
- Stochastic Oscillator
- SSSS 41.11
- ELUT 98.41
About SSSS SuRo Capital Corp.
SuRo Capital Corp is a non-diversified closed-end management investment company. The company's investment objective is to maximize its portfolio's total return, principally by seeking capital gains on its equity and equity-related investments.
About ELUT Elutia Inc.
Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health and Cardiovascular. It generates maximum revenue from the Women's Health segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.